Compare Johnson & Johnson (JNJ) vs Orion Office REIT Inc (ONL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Orion Office REIT Inc — how do they compare? Johnson & Johnson trades at $261.43 (market cap $618.09B), while Orion Office REIT Inc trades at $2.18 (market cap $125.50M). The key difference: Johnson & Johnson is far larger — about 4925× Orion Office REIT Inc's market cap, and Orion Office REIT Inc pays the higher dividend (3.64%). Which is the better fit depends on your goals — on Pluang, investors hold Johnson & Johnson for 129 Days and Orion Office REIT Inc for 33 Days on average.
| JNJ | ONL | |
|---|---|---|
Market Cap | $618.09B | $125.50M |
Volume | 6,050,983 | 303,276 |
Sector | Health | Real Estate |
52-Week High | $278.43 | $3.00 |
52-Week Low | $186.00 | $1.93 |
Typical Hold Time | 129 Days | 33 Days |
Enterprise Value | $646.37B | $542.43M |
Dividend Yield | 2.09% | 3.64% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $261.44, up 1.16% with a bearish technical signal despite recent earnings beats. The company maintains strong fundamentals with $94.19B revenue, 21.48% net margin, and consistent dividend payments. Recent news highlights growth in the Innovative Medicine segment and positive analyst coverage with a $286.53 consensus target.
JNJ offers stable growth potential with diversified healthcare operations and robust profitability. Key risks include patent expirations, competitive pressures, and debt levels. Analyst consensus leans bullish with 52.5% buy ratings, though technical indicators suggest near-term caution. The stock presents a balanced opportunity for long-term investors seeking healthcare exposure.
ONL trades at $2.17, down 4.41% today, with a bearish technical signal from moving averages but bullish oscillators. The REIT shows declining revenue from $208M in 2022 to $148M in 2025, with persistent net losses widening to -$139M. Valuation metrics include P/S of 0.88 and P/B of 0.2, suggesting potential undervaluation, while analyst consensus is split evenly between Buy and Hold ratings. Recent news highlights strategic portfolio repositioning and a declared $0.02 dividend for H2-26.
Outlook remains challenged by operational losses and high leverage, though deep asset discounts and strategic reviews may offer turnaround potential. Key risks include sustained negative margins, debt servicing pressures, and office sector headwinds. Investment appeal hinges on execution of repositioning efforts and margin recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Orion Office REIT Inc
Orion Office REIT Inc is a internally-managed REIT engaged in the ownership, acquisition, and management of a diversified portfolio of mission-critical and headquarters office buildings located in high quality suburban markets across the U.S. and leased primarily on a single-tenant net lease basis to creditworthy clients.
Read more on ONL →
